Alaunos Therapeutics (TCRT) Net Margin (2011 - 2025)
Alaunos Therapeutics' (TCRT) quarterly Net Margin came in at 30233.33% in Q4 2025, down 1135833.0% YoY from N/an in Q4 2024, and up 44.63% on a QoQ basis from 54600.0% in Q1 2025.
Alaunos Therapeutics (TCRT) Net Margin (2011 - 2025) Analysis & Trends
Alaunos Therapeutics (TCRT) has 13 years of Net Margin data on file, last reported at 30233.33% in Q4 2025.
- Quarterly Net Margin fell 1135833.0% year-over-year to 30233.33% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 2439700.0% (down 239807000.0% YoY) and the FY2025 annual result came in at 4356180.0%, down 430806000.0% from the prior year.
- Net Margin advanced to 30233.33% in Q4 2025, from 54600.0% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 85645.45% in Q4 2022 to a low of 809100.0% in Q4 2023.
- A 5-year average of 168539.8% and a median of 30233.33% in 2025 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin tumbled 89474545 bps — and 2024, when it soared 79022500 bps.
- Tracing TCRT's Net Margin over 5 years: stood at 590350.0% in 2021, then soared by 115 bps to 85645.45% in 2022, then plunged by 1045 bps to 809100.0% in 2023, then surged by 98 bps to 18875.0% in 2024, then sank by 60 bps to 30233.33% in 2025.
- The last three Net Margin figures came in at 30233.33% (Q4 2025), 54600.0% (Q1 2025), and 18875.0% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 12.09% |
| 10 | Alaunos Therapeutics | 4.22 Mn | 4.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30,233.33% |
| Mar 31, 2025 | -54,600.00% |
| Dec 31, 2024 | -18,875.00% |
| Jun 30, 2024 | -29,150.00% |
| Mar 31, 2024 | -174,200.00% |
| Dec 31, 2023 | -809,100.00% |
| Jun 30, 2023 | -227,050.00% |
| Dec 31, 2022 | 85,645.45% |
| Sep 30, 2022 | -311.37% |
| Dec 31, 2021 | -590,350.00% |
| Sep 30, 2021 | -5,713.57% |
| Mar 31, 2018 | -14,479.45% |
| Dec 31, 2017 | -1,144.15% |
| Sep 30, 2017 | -1,101.63% |
| Jun 30, 2017 | -1,110.02% |
| Mar 31, 2017 | -1,230.93% |
| Dec 31, 2016 | -923.98% |
| Sep 30, 2016 | -903.94% |
| Jun 30, 2016 | -7,731.29% |
| Mar 31, 2016 | -610.41% |